...
search icon
kapa-img

Kairos Pharma, Ltd. Share Price

KAPA
ASQ
$0.631
+$0
(0%)
1D
Industry: Biotechnology Sector: Health Care

Kairos Pharma, Ltd. Analyst Forecast

Kairos Pharma, Ltd. Share Price Chart

Kairos Pharma, Ltd. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.12M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
20.91K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.4 L
$2.11 H
$0.631

About Kairos Pharma, Ltd., Common Stock

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California. more

Industry: BiotechnologySector: Health Care

Kairos Pharma, Ltd. Stock Returns

Time FrameKAPASectorS&P500
1-Week Return-1.41%0.14%0.86%
1-Month Return-28.39%-0.72%-0.47%
3-Month Return-28.04%3.7%1.34%
6-Month Return-36.04%19.92%8.86%
1-Year Return-53.33%7%14.32%
3-Year Return-75.77%16.96%67.75%

Kairos Pharma, Ltd. Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-98.00K160.00K160.00K160.00K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":61.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit-(98.00K)(160.00K)(160.00K)(160.00K)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-9800000,"profit":false},{"date":"2022-12-31","value":-16000000,"profit":false},{"date":"2023-12-31","value":-16000000,"profit":false},{"date":"2024-12-31","value":-16000000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses1.05M1.84M411.00K1.55M2.18M[{"date":"2020-12-31","value":47.91,"profit":true},{"date":"2021-12-31","value":84.52,"profit":true},{"date":"2022-12-31","value":18.83,"profit":true},{"date":"2023-12-31","value":71.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(1.05M)(1.94M)(571.00K)(1.71M)(2.34M)[{"date":"2020-12-31","value":-104594100,"profit":false},{"date":"2021-12-31","value":-194300000,"profit":false},{"date":"2022-12-31","value":-57100000,"profit":false},{"date":"2023-12-31","value":-171400000,"profit":false},{"date":"2024-12-31","value":-234300000,"profit":false}]
Total Non-Operating Income/Expense(10.82K)(404.00K)(958.00K)(196.00K)(1.12M)[{"date":"2020-12-31","value":-1082200,"profit":false},{"date":"2021-12-31","value":-40400000,"profit":false},{"date":"2022-12-31","value":-95800000,"profit":false},{"date":"2023-12-31","value":-19600000,"profit":false},{"date":"2024-12-31","value":-111900000,"profit":false}]
Pre-Tax Income(1.05M)(2.15M)(1.05M)(1.81M)(2.60M)[{"date":"2020-12-31","value":-105135300,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false},{"date":"2024-12-31","value":-260300000,"profit":false}]
Income Taxes----(2.60M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-260300000,"profit":false}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(1.05M)(2.15M)(1.05M)(1.81M)(2.60M)[{"date":"2020-12-31","value":-105141100,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false},{"date":"2024-12-31","value":-260300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(1.05M)(2.15M)(1.05M)(1.81M)(2.60M)[{"date":"2020-12-31","value":-105135300,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false},{"date":"2024-12-31","value":-260300000,"profit":false}]
EPS (Diluted)----(0.12)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-12,"profit":false}]

Kairos Pharma, Ltd. Ratios

Kairos Pharma, Ltd. Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

KAPA
Cash Ratio 13.87
Current Ratio 16.56

Kairos Pharma, Ltd. Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KAPA
ROA (LTM) -53.59%
ROE (LTM) -92.07%

Kairos Pharma, Ltd. Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KAPA
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Kairos Pharma, Ltd. Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KAPA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.74
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Kairos Pharma, Ltd. share price today?

Kairos Pharma, Ltd. (KAPA) share price today is $0.631

Can Indians buy Kairos Pharma, Ltd. shares?

Yes, Indians can buy shares of Kairos Pharma, Ltd. (KAPA) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KAPA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kairos Pharma, Ltd. be purchased?

Yes, you can purchase fractional shares of Kairos Pharma, Ltd. (KAPA) via the Vested app. You can start investing in Kairos Pharma, Ltd. (KAPA) with a minimum investment of $1.

How to invest in Kairos Pharma, Ltd. shares from India?

You can invest in shares of Kairos Pharma, Ltd. (KAPA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KAPA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kairos Pharma, Ltd. shares
What is Kairos Pharma, Ltd. 52-week high and low stock price?

The 52-week high price of Kairos Pharma, Ltd. (KAPA) is $2.11. The 52-week low price of Kairos Pharma, Ltd. (KAPA) is $0.4.

What is Kairos Pharma, Ltd. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kairos Pharma, Ltd. (KAPA) is

What is Kairos Pharma, Ltd. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kairos Pharma, Ltd. (KAPA) is 1.74

What is Kairos Pharma, Ltd. dividend yield?

The dividend yield of Kairos Pharma, Ltd. (KAPA) is 0.00%

What is the Market Cap of Kairos Pharma, Ltd.?

The market capitalization of Kairos Pharma, Ltd. (KAPA) is $13.12M

What is Kairos Pharma, Ltd.'s stock symbol?

The stock symbol (or ticker) of Kairos Pharma, Ltd. is KAPA

How Can Investors Use Kairos Pharma, Ltd. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Kairos Pharma, Ltd. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kairos Pharma, Ltd. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Kairos Pharma, Ltd. shares for Indian investors?

When investing in Kairos Pharma, Ltd. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kairos Pharma, Ltd. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Kairos Pharma, Ltd. share price with other stocks in the same sector?

Rather than merely checking the share price of Kairos Pharma, Ltd. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kairos Pharma, Ltd. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top